Effect of systemic infliximab therapy in patients with Sjogren's syndrome/Sekonder Sjogren sendromlu hastalarda sistemik infliksimab tedavisinin etkinligi

Objectives: To investigate the effect of systemic infliximab therapy on tear function tests and the ocular surface in patients with Sjogren's syndrome secondary to various autoimmune diseases. Materials and Methods: This prospective study included 22 eyes of 22 patients with Sjogren's syndrome who began treatment with systemic infliximab. Tear film break-up time (TBUT), anesthetized Schirmer's 1 test, fluorescein staining test, and Ocular Surface Disease Index (OSDI) scores were recorded before treatment and in the 3rd and 6th months of treatment. Results: In the 3rd month of infliximab therapy, no significant changes were observed in Schirmer's values, TBUT, fluorescein staining, or OSDI scores (p = 0.260, p = 0.357, p = 0.190 and p = 0.07, respectively). In the 6th month of infliximab therapy, no significant changes were observed in TBUT, fluorescein staining, Schirmer's value or OSDI scores (p = 0.510, p = 0.320, p = 0.220 and p = 0.344, respectively). Conclusion: Infliximab therapy, which is commonly used in systemic autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis, did not show a positive effect on ocular surface and tear function tests. (Turk J Ophthalmol 2015; 45: 138-141) Key Words: Dry eye, infliximab, Sjogren's syndrome, tumor necrosis factor Amac: Cesitli otoimmun hastaliklar ile birliktelik gosteren sekonder Sjogren sendromlu hastalarda sistemik infliksimab tedavisinin okuler yuzey ve gozyasi fonksiyon testlerine etkisini arastirmak. Gerec ve Yontem: Prospektif olarak gerceklestirilen bu calismaya sistemik infliksimab tedavisi baslanan 22 Sjogren sendromlu hastanin 22 gozu dahil edildi. Tedavi oncesinde, tedavinin 3. ve 6. ayinda, gozyasi filmi kirilma zamani (GKZ), anestezili Schirmer 1 testi, floresein ile boyama testi, Okuler Yuzey Hastalik Indeksi (OYHi) skorlari kaydedildi. Bulgular: infliksimab tedavisinin 3. ayinda Schirmer skorlarinda, GKZ'sinde, floresein ile boyama testi ve OYHi degerlerinde anlamli bir degigiklik izlenmedi (sirasiyla p = 0,260, p = 0,357, p = 0,190 ve p = 0,07). infliksimab tedavisinin 6. ayinda da GKZ, floresein ile boyama testi, Schirmer ve OYHi skorlarinda anlamli bir degigiklik olmadigi izlendi (sirasiyla p = 0,510, p = 0,320, p = 0,220 ve p = 0,344). Sonuc: Romatoid artrit, Crohn hastaligi, ulseratif kolit, ankilozan spondilit gibi otoimmun hastaliklarda yaygin olarak kullanilan sistemik infliksimab tedavisinin okuler yuzey ve gozyasi fonksiyon tes